ArticlePsychology research and behavior management2025
A Study on the Effectiveness of Metacognitive Training in Treating Negative Symptoms of Different Subtypes of Schizophrenia.
Article in Psychology research and behavior management, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aims to investigate the efficacy of metacognitive training (MCT) as an adjunctive treatment strategy for schizophrenia, particularly its impact on negative symptoms and potential mechanisms. Patients and Methods: This study included a total of 73 inpatients with schizophrenia. 36 patients were in the MCT group and 37 patients were in the control group. Both groups of patients were receiving a single second-generation antipsychotic drug treatment. The MCT group underwent a 4-week MCT program consisting of 8 modules, while the control group received non-cognitive psychological support for the same duration and frequency. The Positive and Negative Syndrome Scale (PANSS) five-factor model and negative symptom two-factor model were used to assess psychiatric symptoms, and the Snyder's Self-Monitoring Scale (SSMS) and the Personal and Social Performance Scale (PSP) were used as functional evaluation indicators. Results: After treatment, compared to the control group, the MCT group had significantly lower scores in the PANSS total score (p<0.001), negative factor (p=0.002), and hostility factor (p=0.046). Further, the PSP score (p<0.001) and SSMS score (p=0.042) were significantly improved. In the two-factor analysis of negative symptoms, the MCT group showed significant improvements in both diminished expression (DE) symptoms (p<0.001) and social amotivation (SA) symptoms (p=0.010) after treatment. Multivariate linear regression analysis revealed that changes in the reduction rates of P2 (Conceptual disorganization), N7 (stereotyped thinking), and SA scores had a significant impact on the reduction in DE scores; changes in the reduction rates of P6 (Suspiciousness/persecution) and DE scores had a significant impact on the reduction rate of SA scores (p<0.05). Conclusion: MCT can improve the clinical symptoms and functions of patients with schizophrenia, especially in the DE factor characterized by conceptual disorganization and stereotyped thinking, and the SA factor prominent in suspiciousness/persecution symptom. This provides insights for the precise treatment of negative symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.